New research reported molecular profiling work designed to guide targeted and immunotherapy selection in small cell lung cancer (SCLC), a disease marked by rapid progression and heterogeneous biology. The source describes analysis intended to clarify how different molecular subgroups may respond differently, supporting treatment-matching rather than one-size-fits-all approaches. Given that SCLC represents about 15% of lung cancer cases with disproportionate mortality, improved stratification can influence both clinical trial design and routine clinical decision-making. The practical takeaway for the field will be whether the profiles can be translated into actionable companion diagnostics or regimen selection algorithms.